Shandong Wohua Pharmaceutical Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Yingzi Zeng

Geschäftsführender

CN¥552.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	5.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.6yrs

Jüngste Management Updates

Recent updates

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Apr 05

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Mar 08

Geschäftsführer

Yingzi Zeng (61 yo)

4.8yrs

Amtszeit

CN¥552,000

Vergütung

Ms. Yingzi Zeng is President of Shandong Wohua Pharmaceutical Co., Ltd. from December 05, 2019.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yingzi Zeng	President	4.8yrs	CN¥552.00k	keine Daten
Caixia Zhao	Board Secretary & Vice Chairman	5.6yrs	CN¥957.60k	0.0097% CN¥ 237.8k
Jiong Wang	CFO, VP & In Charge of Accounting	13.8yrs	CN¥723.20k	keine Daten
Qian Yang	Deputy General Manager	2.6yrs	CN¥1.71m	keine Daten

5.2yrs

Durchschnittliche Betriebszugehörigkeit

55.5yo

Durchschnittliches Alter

Erfahrenes Management: 002107Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (5.1 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Caixia Zhao	Board Secretary & Vice Chairman	5.6yrs	CN¥957.60k	0.0097% CN¥ 237.8k
Bing Xian Zhao	Chairman of the Board	18.4yrs	keine Daten	keine Daten
Ge Zhang	Director	15.3yrs	CN¥957.60k	1.74% CN¥ 43.0m
Shengting Li	Non-Independent Director	2.6yrs	CN¥684.00k	keine Daten
Wenjun Yin	Non-Employee Chairman of the Board of Supervisors	7.3yrs	keine Daten	keine Daten
Bofang Liu	Non-Employee Supervisor	5.6yrs	keine Daten	keine Daten
Lijuan Liu	Employee Representative Supervisor	5.7yrs	keine Daten	keine Daten
Wanhui Zhou	Supervisor	3.6yrs	keine Daten	0.0016% CN¥ 40.7k
Yong Chen	Non-Independent Director	2.6yrs	CN¥387.50k	keine Daten
Mingqin Gao	Independent Director	2.6yrs	CN¥120.00k	keine Daten
Junli Yu	Independent Director	2.6yrs	CN¥120.00k	keine Daten
Yuesheng Wang	Independent Director	1.4yrs	CN¥70.00k	keine Daten

4.6yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 002107Die Vorstandsmitglieder gelten als erfahren (4.5 Jahre durchschnittliche Amtszeit).

Shandong Wohua Pharmaceutical Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.002 (vs CN¥0.019 in 2Q 2023)

Now 21% undervalued after recent price drop

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 03, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 21%

New major risk - Dividend sustainability

Shandong Wohua Pharmaceutical's (SZSE:002107) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.19 in FY 2022)

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Now 22% overvalued

Subdued Growth No Barrier To Shandong Wohua Pharmaceutical Co., Ltd. (SZSE:002107) With Shares Advancing 28%

Now 23% overvalued

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 20%

Shandong Wohua Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.042 (vs CN¥0.04 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.019 (vs CN¥0.05 in 2Q 2022)

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Jul 29, 2023

Full year 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.28 in FY 2021)

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.06 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 2Q 2021)

Now 21% undervalued after recent price drop

High number of new directors

First quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.09 in 1Q 2021)

High number of new directors

High number of new directors

Shandong Wohua Pharmaceutical Co., Ltd. Announces Executive Appointments

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.081 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.075 in 1Q 2020)

New 90-day low: CN¥7.39

New 90-day low: CN¥7.55

Shandong Wohua Pharmaceutical Co., Ltd., Annual General Meeting, Feb 19, 2021

Full year 2020 earnings released: EPS CN¥0.31

Full year 2020 earnings released: EPS CN¥0.31

Investor sentiment improved over the past week

New 90-day low: CN¥8.10

New 90-day low: CN¥8.90

Third quarter earnings released

Shandong Wohua Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 16, 2020

New 90-day low: CN¥9.24

New 90-day low - CN¥10.07

Shandong Wohua Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Jul 16, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter